Skip to main content

BLRX

Stock
Health Care
Biotechnology

Performance overview

BLRX Price
Price Chart

Forward-looking statistics

Beta
1.37
Risk
100.00%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.

Company info

SectorHealth Care
IndustryBiotechnology
Employees68
Market cap$52.6M

Fundamentals

Enterprise value$10.2B
Revenue$22.3M
Revenue per employee
Profit margin-15.21%
Debt to equity65.87

Security info

ExchangeNASDAQ
Type of shareADR
Earnings per share (EPS)-$6.00
Dividend per share
Revenue per share$9.00
Avg trading volume (30 day)$5M
Avg trading volume (10 day)$247K
Put-call ratio

Macro factor sensitivity

Growth+5.0
Credit+3.8
Liquidity-0.7
Inflation+1.0
Commodities+1.4
Interest Rates-1.6

Valuation

Dividend yield0.00%
PEG Ratio-20.36
Price to sales0.75
P/E Ratio-20.36
Enterprise Value to Revenue456.15
Price to book497.78

Upcoming events

Next earnings dayMarch 28, 2024
Next dividend day
Ex. dividend day

News

Why Is Nano-Cap BioLineRx Stock Surging On Friday?

BioLineRx Ltd's BLRX poster, which includes new data from the single-arm pilot phase of the investigator-initiated, randomized CheMo4METPANC Phase 2 combination trial, will be presented at the 2025 American Society of Clinical Oncology Annual Meeting.

Benzinga (May 30, 2025)
BioLineRx (BLRX) to Report Q2 Earnings: What's in the Cards?

BioLineRx (BLRX) will provide updates on its clinical programs when it releases second-quarter 2020 results.

Zacks Investment Research (July 24, 2020)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free